Another study performed by Quinn et al. presented that out of 111 patients with strong aggregation of breast and ovarian cancer, 57% found PGD as a one of the diagnostic methods of BRCA1 mutation in carriers, while the other 33% were personally interested in using this method[22]. The gene discussed is BRCA1; the disease is ovarian carcinoma.